MRNA vs VRTX
Moderna and Vertex Pharmaceuticals, both Healthcare
Vertex Pharmaceuticals is the larger company at $132B against $82B. Over the past year MRNA returned +658% against +24% for VRTX.
| Figure | MRNA | VRTX |
|---|---|---|
| Last close | $207 | $521 |
| Market cap | $82B | $132B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 30.4 |
| 1-year return | +658% | +24% |
| 5-year return | -36% | +187% |
| RyuScoresector-relative, 1–10 | n/a | 57/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Moderna
Revenue of $145M in Q2 2026, net income null. Its largest reported line is COVID19, 63% of the disclosed total.
Vertex Pharmaceuticals
Revenue of $3.3B in Q2 2026, net income $1.1B. Its largest reported line is TRIKAFTAKAFTRIO, 75% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.